321 related articles for article (PubMed ID: 33109387)
1. FLT3-ITD and CD135 Over-Expression are Frequent Findings of Poor Survival in Adult Patients with Acute Leukemias.
Vela-Ojeda J; Cardenas PV; Garcia-Ruiz Esparza MA; Montiel Cervantes LA; Chavez JG; Caballero AH; Majluf-Cruz A; Vega-López A; Reyes-Maldonado E
Arch Med Res; 2021 Feb; 52(2):217-223. PubMed ID: 33109387
[TBL] [Abstract][Full Text] [Related]
2. Impact of FLT3 Receptor (CD135) Detection by Flow Cytometry on Clinical Outcome of Adult Acute Myeloid Leukemia Patients.
Kandeel EZ; El Sayed G; Elsharkawy N; Eldin DN; Nassar HR; Ibrahiem D; Amin R; Hanafi M; Khalil M; Kamel A
Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):541-547. PubMed ID: 29907544
[TBL] [Abstract][Full Text] [Related]
3. Fms-like tyrosine kinase 3 mutations in childhood acute leukemias and their association with prognosis.
Karabacak BH; Erbey F; Bayram I; Yilmaz S; Acipayam C; Kilinç Y; Tanyeli A
Asian Pac J Cancer Prev; 2010; 11(4):923-7. PubMed ID: 21133602
[TBL] [Abstract][Full Text] [Related]
4. Disease Characteristics and Prognostic Implications of Cell-Surface FLT3 Receptor (CD135) Expression in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group.
Tarlock K; Alonzo TA; Loken MR; Gerbing RB; Ries RE; Aplenc R; Sung L; Raimondi SC; Hirsch BA; Kahwash SB; McKenney A; Kolb EA; Gamis AS; Meshinchi S
Clin Cancer Res; 2017 Jul; 23(14):3649-3656. PubMed ID: 28108543
[No Abstract] [Full Text] [Related]
5. Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia.
Shamaa S; Laimon N; Aladle DA; Azmy E; Elghannam DM; Salem DA; Taalab MM
Hematology; 2014 Jan; 19(1):22-30. PubMed ID: 23540998
[TBL] [Abstract][Full Text] [Related]
6. Increased coexpression of c-KIT and FLT3 receptors on myeloblasts: independent predictor of poor outcome in pediatric acute myeloid leukemia.
Sharawat SK; Gupta R; Raina V; Kumar L; Sharma A; Iqbal S; Bakhshi R; Vishnubhatla S; Bakhshi S
Cytometry B Clin Cytom; 2013; 84(6):390-7. PubMed ID: 23740774
[TBL] [Abstract][Full Text] [Related]
7. High fms-like tyrosine kinase-3 (FLT3) receptor surface expression predicts poor outcome in
Sharawat SK; Raina V; Kumar L; Sharma A; Bakhshi R; Vishnubhatla S; Gupta R; Bakhshi S
Indian J Med Res; 2016 May; 143(Supplement):S11-S16. PubMed ID: 27748272
[TBL] [Abstract][Full Text] [Related]
8. CD34 expression predicts an adverse outcome in patients with NPM1-positive acute myeloid leukemia.
Dang H; Chen Y; Kamel-Reid S; Brandwein J; Chang H
Hum Pathol; 2013 Oct; 44(10):2038-46. PubMed ID: 23701943
[TBL] [Abstract][Full Text] [Related]
9. Aberrant expression of CD7 in myeloblasts is highly associated with de novo acute myeloid leukemias with FLT3/ITD mutation.
Rausei-Mills V; Chang KL; Gaal KK; Weiss LM; Huang Q
Am J Clin Pathol; 2008 Apr; 129(4):624-9. PubMed ID: 18343790
[TBL] [Abstract][Full Text] [Related]
10. Clinical implication and prognostic significance of FLT3-ITD and ASXL1 mutations in Egyptian AML patients: A single-center study.
Ebian HF; Elshorbagy S; Mohamed H; Embaby A; Khamis T; Sameh R; Sabbah NA; Hussein S
Cancer Biomark; 2021; 32(3):379-389. PubMed ID: 34487021
[TBL] [Abstract][Full Text] [Related]
11. Clinical Effect of Combined Mutations in DNMT3A, FLT3-ITD, and NPM1 Among Egyptian Acute Myeloid Leukemia Patients.
El Gammal MM; Ebid GT; Madney YM; Abo-Elazm OM; Kelany AK; Torra OS; Radich JP
Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):e281-e290. PubMed ID: 30926392
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia.
Santos FP; Jones D; Qiao W; Cortes JE; Ravandi F; Estey EE; Verma D; Kantarjian H; Borthakur G
Cancer; 2011 May; 117(10):2145-55. PubMed ID: 21523727
[TBL] [Abstract][Full Text] [Related]
13. FLT3-ITD Compared with DNMT3A R882 Mutation Is a More Powerful Independent Inferior Prognostic Factor in Adult Acute Myeloid Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study.
Ardestani MT; Kazemi A; Chahardouli B; Mohammadi S; Nikbakht M; Rostami S; Jalili M; Vaezi M; Alimoghaddam K; Ghavamzadeh A
Turk J Haematol; 2018 Aug; 35(3):158-167. PubMed ID: 29786546
[TBL] [Abstract][Full Text] [Related]
14. Concomitant ABCG2 overexpression and FLT3-ITD mutation identify a subset of acute myeloid leukemia patients at high risk of relapse.
Tiribelli M; Geromin A; Michelutti A; Cavallin M; Pianta A; Fabbro D; Russo D; Damante G; Fanin R; Damiani D
Cancer; 2011 May; 117(10):2156-62. PubMed ID: 21523728
[TBL] [Abstract][Full Text] [Related]
15. Risk assessment in patients with acute myeloid leukemia and a normal karyotype.
Bienz M; Ludwig M; Leibundgut EO; Mueller BU; Ratschiller D; Solenthaler M; Fey MF; Pabst T
Clin Cancer Res; 2005 Feb; 11(4):1416-24. PubMed ID: 15746041
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of FLT3-ITD length in AML patients treated with intensive regimens.
Castaño-Bonilla T; Alonso-Dominguez JM; Barragán E; Rodríguez-Veiga R; Sargas C; Gil C; Chillón C; Vidriales MB; García R; Martínez-López J; Ayala R; Larrayoz MJ; Anguita E; Cuello R; Cantalapiedra A; Carrillo E; Soria-Saldise E; Labrador J; Recio I; Algarra L; Rodríguez-Medina C; Bilbao-Syeiro C; López-López JA; Serrano J; De Cabo E; Sayas MJ; Olave MT; Sánchez-García J; Mateos M; Blas C; López-Lorenzo JL; Lainez-Gonzalez D; Serrano J; Martínez-Cuadrón D; Sanz MA; Montesinos P
Sci Rep; 2021 Oct; 11(1):20745. PubMed ID: 34671057
[TBL] [Abstract][Full Text] [Related]
17. The impact of FLT3 mutation clearance and treatment response after gilteritinib therapy on overall survival in patients with FLT3 mutation-positive relapsed/refractory acute myeloid leukemia.
Altman JK; Perl AE; Hill JE; Rosales M; Bahceci E; Levis MJ
Cancer Med; 2021 Feb; 10(3):797-805. PubMed ID: 33340276
[TBL] [Abstract][Full Text] [Related]
18. [Flt-3/ITD mutation in pediatric leukemia and its clinical significance].
Wang J; Wang T; Li S; Lin L; Gang Y
Ai Zheng; 2007 Jan; 26(1):58-63. PubMed ID: 17222369
[TBL] [Abstract][Full Text] [Related]
19. FLT3-ITD and CEBPA Mutations Predict Prognosis in Acute Myelogenous Leukemia Irrespective of Hematopoietic Stem Cell Transplantation.
Wang H; Chu TT; Han SY; Qi JQ; Tang YQ; Qiu HY; Fu CC; Tang XW; Ruan CG; Wu DP; Han Y
Biol Blood Marrow Transplant; 2019 May; 25(5):941-948. PubMed ID: 30503388
[TBL] [Abstract][Full Text] [Related]
20. Allogeneic Stem Cell Transplantation Improves Survival in Patients with Acute Myeloid Leukemia Characterized by a High Allelic Ratio of Mutant FLT3-ITD.
Ho AD; Schetelig J; Bochtler T; Schaich M; Schäfer-Eckart K; Hänel M; Rösler W; Einsele H; Kaufmann M; Serve H; Berdel WE; Stelljes M; Mayer J; Reichle A; Baldus CD; Schmitz N; Kramer M; Röllig C; Bornhäuser M; Thiede C; Ehninger G;
Biol Blood Marrow Transplant; 2016 Mar; 22(3):462-9. PubMed ID: 26551637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
